Dr. Tse is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 646-227-3813
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
Keck School of Medicine of the University of Southern CaliforniaClass of 1997
Certifications & Licensure
NY State Medical License 2002 - 2025
Clinical Trials
- Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2004 Mar 01
- 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2005 May 01
Publications & Presentations
PubMed
- 310 citationsMulticenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaManish A. Shah, Ramesh K. Ramanathan, David H. Ilson, Alissa Levnor, David R. D'Adamo
Journal of Clinical Oncology. 2006-11-20 - 81 citationsPotentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Result...Archie N. Tse, Gary K. Schwartz
Cancer Research. 2004-09-15 - 864 citationsCetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by ImmunohistochemistryKi Y. Chung, Jinru Shia, Nancy E. Kemeny, Manish A. Shah, Gary K. Schwartz
Journal of Clinical Oncology. 2005-03-20
Press Mentions
CStone Presents Research Data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021October 8th, 2021- CStone Presents Preliminary Results from a Phase Ib Study of the Anti-CTLA-4 Monoclonal Antibody (mAb) CS1002 in Combination with the Anti-PD-1 mAb CS1003 in Patients with Advanced Solid Tumors at ESMO 2021September 19th, 2021
- CStone Received China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0September 15th, 2021
- Join now to see all
Grant Support
- Targeting Cell Cycle Checkpoints In Cancer TherapeuticsNational Cancer Institute2006–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
